Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Hannah Van BelleSara Alsterlind HurvitzPeter Jeffrey GilbarHans P M W WildiersPublished in: Breast cancer research and treatment (2021)
The crude FN risk associated with (neo)adjuvant TCH(P) is over 20%, the upper limit above which the international guidelines unanimously advise PP G-CSF administration. G-CSF prophylaxis effectively reduces FN risk and should become the standard of care with (neo)adjuvant TCH(P).